Tempus AI (TEM) drew fresh investor attention after announcing a research collaboration with Angiosarcoma Awareness, Inc., using roughly 600 de-identified angiosarcoma records to support data driven work in this rare cancer.

The recent collaboration news comes as Tempus AI trades at US$56.14, with strong short term momentum reflected in a 1 month share price return of 19.02% and 3 month share price return of 31.72%. This is set against a softer year to date share price return that has declined 9.97% and a 1 year total shareholder return that has fallen 15.60%, suggesting recent enthusiasm is picking up after a tougher stretch for longer term holders.

If this kind of precision medicine story interests you, it may be worth broadening your watchlist using a screener focused on 39 healthcare AI stocks

With Tempus AI now trading at US$56.14, recent gains and an indicated 34.67% intrinsic discount raise a key question for investors: is there still a potential opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 14.8% Undervalued

At a last close of $56.14 versus a narrative fair value of $65.90, the most followed view on Tempus AI sees meaningful upside still on the table.

This data moat is what makes the business interesting.

Tempus has accumulated tens of millions of de-identified patient records and hundreds of petabytes of clinical and molecular data, assets that would take competitors years and enormous investment to replicate.

Want to understand why this valuation leans so heavily on scale and mix, not hype and headlines? The narrative leans on compounding revenue, rising margins, and a future profit multiple usually reserved for established software platforms. Curious which specific growth and profitability assumptions sit underneath that $65.90 figure and how they interact over time?

Result: Fair Value of $65.90 (UNDERVALUED)

However, Tempus AI still faces clear swing factors, including ongoing net losses of $302.91 million and the risk that healthcare partners may adopt competing AI and data platforms.

Another View: Tempus AI Looks Expensive on Sales

The first narrative points to upside based on future cash flows, but the current P/S ratio of 7.4x tells a different story. Tempus AI trades above its own fair ratio of 7.3x, the US Life Sciences industry at 4x, and peer average of 4.4x, which suggests investors are already paying a premium for growth that has to be earned.

For readers who put more weight on simple market comparisons than on modeled cash flows, this richer P/S multiple can look like valuation risk rather than a margin of safety. The real question is which lens you trust more when growth expectations are tested next.

Next Steps

Given the mixed sentiment around Tempus AI, it helps to move quickly from headlines to hard numbers and evaluate both the concerns and the upside potential yourself using 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Tempus AI?

If you like what Tempus AI is doing but want a broader watchlist, do not sit on your hands while other opportunities move without you.

• Target potential mispricings by scanning a curated set of 44 high quality undervalued stocks that pair solid fundamentals with attractive entry points.
• Prioritise resilience by focusing on 71 resilient stocks with low risk scores that score well on balance sheet strength and business stability.
• Get ahead of the crowd by tracking a screener containing 19 high quality undiscovered gems before they sit firmly on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.